Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• Central Subfield Thickness (CST) and Central Retina Thickness (CRT): Faricimab significantly reduced CST and CRT in treated eyes, demonstrating comparable retinal thickness outcomes to other anti-VEGF agents, except for brolucizumab, which showed superior results. In diabetic macular edema (DME), faricimab achieved superior retinal drying compared to other anti-VEGF therapies.
• Visual Acuity (BCVA): Faricimab maintained BCVA in previously treated eyes and improved BCVA in treatment-naive eyes. There were no statistically significant differences in BCVA outcomes compared to other anti-VEGF agents in neovascular age-related macular degeneration (nAMD).
• Injection Frequency: Faricimab required fewer injections annually compared to other anti-VEGF agents in both AMD (age-related macular degeneration) and DME populations.
• Faricimab was generally well-tolerated, with no significant safety concerns identified.
• A higher risk of vitreous floaters was associated with faricimab use compared to the control group, with no statistically significant differences in ocular adverse events or serious ocular adverse events compared to anti-VEGF agents.
• There is no population types or subgroups information available in the reviewed documents.